Genentech gets cancer drug from Hanmi | Chemical & Engineering News
Volume 94 Issue 39 | pp. 17-18 | Concentrates
Issue Date: October 3, 2016

Genentech gets cancer drug from Hanmi

Department: Business
Keywords: drug development, cancer, oncology, RAF inhibitor

Genentech has licensed a small-molecule oncology treatment from the South Korean drug company Hanmi Pharmaceutical. Genentech will pay $80 million up front and up to $830 million in milestone payments for worldwide rights, except in South Korea, to HM95573, a pan-RAF inhibitor that is in Phase I clinical trials. RAF kinases are mitogen-activated protein kinases that are known to be associated with various cancers. Genentech says it has worked in this area for 25 years.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment